bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-5070-01

Order Name:
HLA-B 5701 - Please use order Pharmacogenomics in HLA-B **

 
Useful For:
Genotyping for HLA-B*57:01 before abacavir therapy, or taking pazopanib.
 
Methodology:
Polymerase chain reaction
 
AliasesName:
Pharmacogenetic for HLA-B*57:01
Abacavir Hypersensitivity
Pazopanib liver, hepatotoxicity
Pazopanib induced elevated serum transaminases
HLAB5701
HLA B*57:01
 
 
 
Test Code:
090-71-5070-01

Order Name:
HLA-B 5701 - Please use order Pharmacogenomics in HLA-B **

 
Collection Specimen Or Container:
Blood/ K3 EDTA (Lavender Top) 3 mL, 2 tubes
 
Specimen Testing Type:
Whole Blood EDTA, minimum volume 3 mL
 
Sub Mission Container:
Original tube
 
Rejection Criteria:
Hemolysis: Hemolysis interfere
Other: Over Stability will be reject
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood, EDTA Ambient (preferred) Same day
  Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code:
090-71-5070-01

Order Name:
HLA-B 5701 - Please use order Pharmacogenomics in HLA-B **

 
Method detail:
Polymerase chain reaction
 
Schedule:
N/A **Sent Out to Ramathibodi
 
Turnaround Time:
Reported within 3-5 days (exception for official holidays)
 
Performing Location:
Ramathibodi
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-5070-01

Order Name:
HLA-B 5701 - Please use order Pharmacogenomics in HLA-B **

 
 
Clinical Information:
The HLA-B*57:01 allele has been associated with hypersensitivity to abacavir, a highly effective nucleoside analog reverse-transcriptase inhibitor used to treat HIV infection and AIDS. Per the Clinical Pharmacogenomics Implementation Consortium (CPIC) dosing guidelines for abacavir and HLA-B, individuals who are positive for the HLA-B*57:01 allele are at an increased risk for abacavir hypersensitivity and it is not recommended for use in treating these individuals. HLA-B*57:01 carriers who are taking pazopanib are at increased risk of elevated ALT levels.
 
Reference Value:
Negative
 
Interpretation:
Positivity for human leukocyte antigen allele HLA-B*57:01 confers high risk for hypersensitivity to abacavir and higher risk of elevated alanine aminotransferase levels in patient taking pazopanib.
 
Clinical Reference:
  1. www.si.mahidol.ac.th (Retrieved: 18 Jan 2019)
  2. www.mayomedicallaboratories.com (Retrieved: 18 Jan 2019)